公开(公告)号：US11793788B2

公开(公告)日：2023-10-24

申请号：US16440761

申请日：2019-06-13

Applicant: AstraZeneca UK Limited

Inventor： Robert Peter Prybolsky ,  Judy Firor

IPC: A61K31/403 ,  G16H70/40 ,  G16H10/20 ,  A61P3/10 ,  G06F16/9038 ,  G06F16/9035 ,  A61K31/513 ,  A61K31/522 ,  G06F9/54

CPC classification number: A61K31/403 ,  A61K31/513 ,  A61K31/522 ,  A61P3/10 ,  G06F9/542 ,  G06F16/9035 ,  G06F16/9038 ,  G16H10/20 ,  G16H70/40

Abstract: A method is provided for lowering blood sugar in a subject in need thereof by administering a dipeptidyl peptidase-4 inhibitor pharmaceutical composition to a subject qualified for over-the-counter access to the dipeptidyl peptidase-4 inhibitor pharmaceutical composition. In some embodiments, the dipeptidyl peptidase-4 inhibitor pharmaceutical composition includes saxagliptin, sitagliptin, linagliptin, alogliptin, or a pharmaceutically acceptable salt thereof. In some embodiments, the dipeptidyl peptidase-4 inhibitor pharmaceutical composition includes (1S,3S,5S)-2-[(2S)-2-amino-2-(3-hydroxy-1-adamantyl)acetyl]-2-azabicyclo[3.1.0]hexane-3-carbonitrile or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20230242626A1

公开(公告)日：2023-08-03

申请号：US18052840

申请日：2022-11-04

Applicant: AstraZeneca UK Limited

Inventor： Albert SCHMELZER ,  Sajal PATEL ,  Annette MEDINA ,  Austin GALLEGOS

IPC: C07K16/10 ,  A61P31/14

CPC classification number: C07K16/10 ,  A61P31/14 ,  C07K2317/565

Abstract: The present disclosure provides pharmaceutical compositions comprising antibodies and antigen-binding fragments thereof that specifically bind to the spike protein of SARS-CoV-2 the prevention and treatment of Coronavirus Disease 2019 (COVID-19) in a subject.

公开(公告)号：US20230046548A1

公开(公告)日：2023-02-16

申请号：US17862342

申请日：2022-07-11

Applicant: AstraZeneca UK Limited

Inventor： Richard L. Skelly ,  Judy Firor

IPC: G16H10/20 ,  G16H10/40 ,  G16H10/60 ,  G16H70/40 ,  G16H20/10

Abstract: A method is provided for lowering blood pressure in a subject in need thereof by administering a dihydropyridine-type calcium channel blocker pharmaceutical composition to a subject qualified for over-the-counter access to the dihydropyridine-type calcium channel blocker pharmaceutical composition. In some embodiments, the dihydropyridine-type calcium channel blocker pharmaceutical composition includes isradipine, nifedipine, or nisoldipine. In some embodiments, the dihydropyridine-type calcium channel blocker pharmaceutical composition includes 3-O-ethyl 5-O-methyl 2-(2-aminoethoxymethyl)-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate or a pharmaceutically acceptable salt thereof.

公开(公告)号：US11501857B2

公开(公告)日：2022-11-15

申请号：US16440787

申请日：2019-06-13

Applicant: AstraZeneca UK Limited

Inventor： Robert Peter Prybolsky ,  Judy Firor

IPC: G16H10/40 ,  G16H50/30 ,  G16H20/10

Abstract: A method is provided for lowering blood sugar in a subject in need thereof by administering a biguanide anti-hyperglycemic pharmaceutical composition to a subject qualified for over-the-counter access to the biguanide anti-hyperglycemic pharmaceutical composition. In some embodiments, the biguanide anti-hyperglycemic pharmaceutical composition includes N,N-dimethylimidodicarbonimidic diamide, or a pharmaceutically acceptable salt thereof. In some embodiments, the biguanide anti-hyperglycemic pharmaceutical composition includes metformin hydrochloride.

公开(公告)号：US20220184156A1

公开(公告)日：2022-06-16

申请号：US17547323

申请日：2021-12-10

Applicant: ASTRAZENECA UK LIMITED

Inventor： JINLIN JIANG ,  NICOLE BLECKWENN ,  RAGHAVAN VENKAT ,  DANIEL PAPPAS ,  BENJAMIN RUSH ,  GEORGE CHACKO

IPC: A61K35/761 ,  C12N7/00 ,  A61K39/235

Abstract: Methods for the production of adenoviruses which are suitable for use in a vaccine, and methods for increasing the yield of adenoviruses during production. These methods include adding an adenovirus to a cell population in culture; culturing the cell population under conditions which are permissive for infection of the cell population with the adenovirus to provide a cell population comprising adenovirus-infected cells; culturing the cell population comprising adenovirus-infected cells under conditions which are permissive for replication of the adenovirus; and harvesting the adenovirus from the culture.

公开(公告)号：US20190385712A1

公开(公告)日：2019-12-19

申请号：US16440787

申请日：2019-06-13

Applicant: AstraZeneca UK Limited

Inventor： Robert Peter Prybolsky ,  Judy Firor

IPC: G16H10/40 ,  G16H20/10 ,  G16H50/30

Abstract: A method is provided for lowering blood sugar in a subject in need thereof by administering a biguanide anti-hyperglycemic pharmaceutical composition to a subject qualified for over-the-counter access to the biguanide anti-hyperglycemic pharmaceutical composition. In some embodiments, the biguanide anti-hyperglycemic pharmaceutical composition includes N,N-dimethylimidodicarbonimidic diamide, or a pharmaceutically acceptable salt thereof. In some embodiments, the biguanide anti-hyperglycemic pharmaceutical composition includes metformin hydrochloride.

公开(公告)号：US10028953B2

公开(公告)日：2018-07-24

申请号：US15364607

申请日：2016-11-30

Applicant: AstraZeneca UK Limited

Inventor： Joseph Richard Creekmore ,  Sanjeev Hukmichand Kothari ,  Bradford J. Mueller ,  Yingxu Peng

IPC: A61K31/505 ,  A61K31/616 ,  A61K9/28 ,  A61K9/16 ,  A61K9/20 ,  A61K9/50 ,  A61K9/24 ,  A61K31/155 ,  A61K31/455

CPC classification number: A61K31/505 ,  A61K9/167 ,  A61K9/1676 ,  A61K9/1694 ,  A61K9/2086 ,  A61K9/209 ,  A61K9/2813 ,  A61K9/282 ,  A61K9/2866 ,  A61K9/2886 ,  A61K9/2893 ,  A61K9/501 ,  A61K9/5015 ,  A61K9/5042 ,  A61K9/5073 ,  A61K9/5078 ,  A61K31/155 ,  A61K31/455 ,  A61K31/616 ,  A61K2300/00

Abstract: The invention relates to pharmaceutical compositions containing rosuvastatin calcium of formula (I) and processes for their manufacture.

公开(公告)号：US20180133216A1

公开(公告)日：2018-05-17

申请号：US15707376

申请日：2017-09-18

Applicant: AstraZeneca UK Limited

Inventor： Michael Karl Bechtold ,  Julie Kay Cahill ,  Katja Maren Fastnacht ,  Kieran James Lennon ,  Bernd Harald Liepold ,  Claudia Bettina Packhaeuser ,  Benedikt Steitz

IPC: A61K31/502 ,  A61K47/20 ,  A61K47/02 ,  A61K47/12 ,  A61K9/20 ,  A61K47/32

CPC classification number: A61K31/502 ,  A61K9/2009 ,  A61K9/2013 ,  A61K9/2027 ,  A61K9/2095 ,  A61K47/02 ,  A61K47/12 ,  A61K47/20 ,  A61K47/32

Abstract: The present invention relates to a pharmaceutical formulation comprising the drug 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one in a solid dispersion with a matrix polymer that exhibits low hygroscopicity and high softening temperature, such as copovidone. The invention also relates to a daily pharmaceutical dose of the drug provided by such a formulation. In addition, the invention relates to the use of a matrix polymer that exhibits low hygroscopicity and high softening temperature in solid dispersion with 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one for increasing the bioavailability of the drug.

公开(公告)号：US20160324854A1

公开(公告)日：2016-11-10

申请号：US15109170

申请日：2015-01-02

Applicant: ASTRAZENECA AB ,  ASTRAZENECA UK LIMITED

Inventor： Cindy FINNIE ,  Steven Anthony RAW ,  David WILSON

IPC: A61K31/506 ,  A61K9/00 ,  A61K9/28 ,  A61K9/20

CPC classification number: A61K31/506 ,  A61K9/0053 ,  A61K9/2054 ,  A61K9/28

Abstract: The present invention relates to pharmaceutical compositions suitable for oral administration, and more particularly to pharmaceutical compositions, including pharmaceutical tablet compositions, containing N-(2-{2-dimethylaminoethyl-methyl-amino}-4-methoxy-5-[4-(1-methylindol-3-yppyrimidin-2-yl]amino phenyl)prop-2-enamide (“AZD9291”) or a pharmaceutically Cacceptable salt thereof, wherein such compositions comprise a certain amount of microcrystalline cellulose and at least one other pharmaceutical diluent.

Abstract translation: 本发明涉及适于口服给药的药物组合物，更具体地涉及包含N-（2- {2-二甲氨基乙基 - 甲基 - 氨基} -4-甲氧基-5- [4-（ 1-甲基吲哚-3-基嘧啶-2-基]氨基苯基）丙-2-烯酰胺（“AZD9291”）或其药学上可接受的盐，其中所述组合物包含一定量的微晶纤维素和至少一种其它药物稀释剂。

公开(公告)号：US20150152111A1

公开(公告)日：2015-06-04

申请号：US14310315

申请日：2014-06-20

Applicant: AstraZeneca UK Limited

Inventor： David Hardern ,  Anthony Ingall ,  Brian Springthorpe ,  Paul Willis ,  Simon Guile

IPC: C07D487/04

CPC classification number: C07D487/04 ,  A61K31/519 ,  C07C211/40 ,  C07D239/48

Abstract: The invention provides new triazolo[4,5-d]pyrimidine compounds, their use as medicaments, compositions containing them and processes for their preparation.

Abstract translation: 本发明提供新的三唑并[4,5-d]嘧啶化合物，它们作为药物的用途，含有它们的组合物及其制备方法。